Supporting this approach, previous studies [44–46] and KEGG pathway enrichment analysis of RNA-seq data from PLK1 inhibitor-treated EGFR-mutant NSCLC cells demonstrated that PLK1 inhibition predominantly affects several critical signaling pathways, including those involved in apoptosis and EGFR-TKI resistance mechanisms. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.